A key HDAC6 dependency of ARID1A-mutated ovarian cancer

被引：0
|
作者：
Lucia Altucci
机构：
[1] Biofisica e Patologia generale,Dipartimento di Biochimica
[2] Università degli Studi della Campania 'Luigi Vanvitelli',undefined
来源：
Nature Cell Biology | 2017年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Mutations in AT rich interactive domain 1A (ARID1A) are common in ovarian cancers. A study now shows that HDAC6 activity is required for survival of ovarian cancer cells bearing ARID1A mutations. HDAC6 inhibition selectively promotes apoptosis of ARID1A-inactivated cells, supporting the use of HDAC6 inhibition in the treatment of clear cell ovarian cancer.
引用
收藏
页码：889 / 890
页数：1
相关论文
共 50 条
  • [1] A key HDAC6 dependency of ARID1A-mutated ovarian cancer
    Altucci, Lucia
    [J]. NATURE CELL BIOLOGY, 2017, 19 (08) : 889 - 890
  • [2] ARID1A-mutated ovarian cancers depend on HDAC6 activity
    Bitler, Benjamin G.
    Wu, Shuai
    Park, Pyoung Hwa
    Hai, Yang
    Aird, Katherine M.
    Wang, Yemin
    Zhai, Yali
    Kossenkov, Andrew V.
    Vara-Ailor, Ana
    Rauscher, Frank J., III
    Zou, Weiping
    Speicher, David W.
    Huntsman, David G.
    Conejo-Garcia, Jose R.
    Cho, Kathleen R.
    Christianson, David W.
    Zhang, Rugang
    [J]. NATURE CELL BIOLOGY, 2017, 19 (08) : 962 - +
  • [3] ARID1A-mutated ovarian cancers depend on HDAC6 activity
    Benjamin G. Bitler
    Shuai Wu
    Pyoung Hwa Park
    Yang Hai
    Katherine M. Aird
    Yemin Wang
    Yali Zhai
    Andrew V. Kossenkov
    Ana Vara-Ailor
    Frank J. Rauscher III
    Weiping Zou
    David W. Speicher
    David G. Huntsman
    Jose R. Conejo-Garcia
    Kathleen R. Cho
    David W. Christianson
    Rugang Zhang
    [J]. Nature Cell Biology, 2017, 19 : 962 - 973
  • [4] Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
    Fukumoto, Takeshi
    Park, Pyoung Hwa
    Wu, Shuai
    Fatkhutdinov, Nail
    Karakashev, Sergey
    Nacarelli, Timothy
    Kossenkov, Andrew V.
    Speicher, David W.
    Jean, Stephanie
    Zhang, Lin
    Wang, Tian-Li
    Shih, Ie-Ming
    Conejo-Garcia, Jose R.
    Bitler, Benjamin G.
    Zhang, Rugang
    [J]. CELL REPORTS, 2018, 22 (13): : 3393 - 3400
  • [5] COMBINATIONAL TARGETING OF HDAC6 AND PD-1/PD-L1 IMMUNE CHECKPOINT IN ARID1A-MUTATED OVARIAN CANCERS
    Fatkhutdinov, Nail
    Fukumoto, Takeshi
    Zhang, Rugang
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (22) : 158 - 158
  • [6] Therapeutic approaches for ARID1A-mutated ovarian cancer.
    Zhang, Rugang
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (13) : 26 - 26
  • [7] HDAC6 and Ovarian Cancer
    Haakenson, Joshua
    Zhang, Xiaohong
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (05) : 9514 - 9535
  • [8] HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
    Fukumoto, Takeshi
    Fatkhutdinov, Nail
    Zundell, Joseph A.
    Tcyganov, Evgenii N.
    Nacarelli, Timothy
    Karakashev, Sergey
    Wu, Shuai
    Liu, Qin
    Gabrilovich, Dmitry I.
    Zhang, Rugang
    [J]. CANCER RESEARCH, 2019, 79 (21) : 5482 - 5489
  • [9] ARID1A-mutated cervical cancer depends on the activation of YAP signaling
    Gao, Fei
    Li, Peiling
    Kong, Xianchao
    Song, Tiefang
    Han, Qi
    Zhou, Suiyang
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2021, 26 (12): : 1411 - 1421
  • [10] Potential therapeutic targets in ARID1A-mutated cancers
    Bitler, Benjamin G.
    Fatkhutdinov, Nail
    Zhang, Rugang
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (11) : 1419 - 1422
12345